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Tuneable endogenous mammalian 
target complementation via 
multiplexed plasmid-based 
recombineering
Violeta Beltran-Sastre1,2,*, Hannah Benisty1,2,*, Julia Burnier1,2, Imre Berger3,4, 
Luis Serrano1,2,5 & Christina Kiel1,2
Understanding the quantitative functional consequences of human disease mutations requires 
silencing of endogenous genes and expression of mutants at close to physiological levels. Changing 
protein levels above or below these levels is also important for system perturbation and modelling. 
Fast design optimization demands flexible interchangeable cassettes for endogenous gene silencing 
and tuneable expression. Here, we introduce ‘TEMTAC’, a multigene recombineering and delivery 
system for simultaneous siRNA-based knockdown and regulated mutant (or other variant) expression 
with different dynamic ranges. We show its applicability by confirming known phenotypic effects for 
selected mutations for BRAF, HRAS, and SHP2.
Recent work provided evidence that quantitative rather than qualitative differences in the proteomic 
inventory between different cell types and tissues are the cause of functional differences1–7. Thus, to inves-
tigate cell type-specific quantitative consequences of disease mutations or alternative spliced variants, it 
is of crucial importance to combine knockdown of the endogenous protein(s) with the precise regulated 
expression of the mutant protein(s) to the desired physiological level.
Gene silencing based on short interfering RNAs (siRNA) has been demonstrated in several organ-
isms, including in cultured mammalian cells8, and works by targeting complementary messenger RNA 
(mRNA) thereby activating the RISC complex causing sequence-specific mRNA degradation. Short hair-
pin RNAs (shRNAs) can also be stably expressed downstream of polymerase III (Pol III) promoters9 or 
bidirectionally co-expressed10. Advanced genome editing technologies such as meganucleases, zinc fin-
ger nucleases, TALENS (protein-DNA guided), and the RNA-guided CRISPR-Cas9 and CRISPRi-dCas9 
methods complement the available tools for gene silencing, each with their own merits11,12. However, 
despite these being powerful tools, they could modify the genome irreversibly and have other draw-
backs. These may include off-target mutagenesis, although in some cases they have been significantly 
diminished13, and often cumbersome and time-consuming selection/screening to identify the appropri-
ate clone, which is refractory to high-throughput14.
Plasmid-based gene delivery systems have become essential for molecular and cell biology. However, 
the number of available selection markers and the physical space that needs to be available to allow entry 
of multiple plasmids into cells are technically limiting. These problems are exacerbated by imbalanced 
delivery if multiple plasmids are used, resulting in heterogeneous cell populations which interferes with 
read-out. These impediments can be circumvented by combining independent modules containing genes 
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of interest, regulatory elements and other desired functionalities into a single multifunctional multigene 
delivery plasmid. This is a viable option if the combination of the modules is sufficiently straight-forward. 
Addressing this challenge, we previously developed the ‘ACEMBL’ system to enable fast and flexible 
generation of multigene delivery constructs by an automatable technique called tandem recombineering 
(TR) to combine ‘Donor’ and ‘Acceptor’ plasmid modules via reversible Cre-loxP fusion in vitro, option-
ally in high-throughput by robotics15,16. We implemented ACEMBL successfully for complex expressions 
in prokaryotic and eukaryotic cells. However, a useful tool that would afford the means to combine 
efficient DNA delivery with regulated heterologous expression and efficient silencing in cell-based com-
plementation assays remained elusive to date.
Here, we introduce TEMTAC, a novel system for Tunable Endogenous Mammalian TArget 
Complementation by multiplexed plasmid-based recombineering. Retaining the original ACEMBL con-
cept, we developed this novel system which affords the means to simultaneously knockdown endoge-
nous targets via RNA interference8–10 and express mutated versions utilizing regulated tetracycline (TET) 
controlled transcriptional activation17. Three modules are combined, one each for (i) shRNA-mediated 
silencing, (ii) TET-regulated expression of the mutant gene of interest (GOI) that contains silent muta-
tions to forestall its own degradation, and (iii) integration of the complete composite plasmid, which 
expresses an additional YFP marker gene for identifying transfected cells by fluorescence (Fig. 1a). The 
three modules can be easily assembled and disassembled in vitro exploiting the Cre-Lox recombina-
tion reaction, which can be carried out optionally in high-throughput by robotics applying automated 
routines we have implemented16. The separate modules also work autonomously, for example to test 
proper functioning of each individual element prior to multigene recombineering. A homing endonu-
clease (HE)/BstXI based multiplication module15 is provided to enable engineering within each Donor or 
Acceptor, if several proteins, for example entire regulatory cascades, are to be complemented concomi-
tantly. As a further option, TEMTAC also affords stable integration into cellular genomes, by providing 
on the Acceptor module eukaryotic resistance markers and the DNA elements required. We demonstrate 
the utility of TEMTAC utilizing proteins of the ErbB signalling network, HRAS, BRAF, and SHP2. By 
using TEMTAC, we silence the proteins of interest, express corresponding mutants, and test these for 
signalling phenotypes, compellingly validating our approach.
Results
Endogenous gene silencing module. Donor D1 (pMDC-RNAiDual) contains the silencing cassette 
for knocking down the endogenous gene by RNA interference (Fig. 1b). In one Donor D1, two shRNAs 
can be bi-directionally co-expressed downstream of H1 and U6 Pol III promoters. This allows the test-
ing of the silencing effects of multiple shRNA hairpin sequences. In addition, previous work has shown 
that silencing effects are often additive and that combination therefore increases knockdown efficiency, 
without cumulative off-target effects18. We tested the silencing effect of the independent Donor D1 for 
three proteins. For BRAF and SHP2, we inserted two published siRNA sequences19–22 into Donor D1. 
In the case of RAS we cloned new shRNAs which we designed using online software (http://www.invi-
vogen.com/sirna-wizard). Donor D1 containing the shRNAs was transiently transfected in HEK293 or 
HeLa cells. After 24 and 48 hours, cells were lysed and endogenous protein levels detected by Western 
blotting, real time PCR, and deep sequencing. We observed the best silencing effect 48 h post transfec-
tion and no (or small) down-regulation using random (‘scrambled’ scrb) shRNAs as a control (Fig. 1c 
and Supplementary Figs. 1 to 4). Incomplete silencing will depend on the efficiency/specificity of the 
respective shRNA’s used. A further aspect is that transfection is transient and the transfection efficiency 
is small than 80-90% in most cell lines.
Inducible exogenous mutant expression module. Achieving expression levels that are close to 
endogenous levels is a crucial prerequisite for analysing the physiological effect of mutations. This is 
particularly important when studying signalling proteins because of their frequent involvement in down-
stream activation and feedback loops, which often function at very precise protein levels that need to be 
maintained meticulously. A major problem in many TET regulated systems is basal expression (with-
out the inducer being present), especially for proteins that are present at markedly low abundance in 
cells. Furthermore, depending on the protein of interest, different dynamic expression ranges of mutants 
would be highly desirable to properly recapitulate physiological events. To address this, we created as 
Donor D2 variants four different TET-related expression system versions with defined properties (Donor 
D2.1 to D2.4, Fig. 1d and Supplementary Fig. 5).
(a)  Donor D2.1 (pMDS-GOI-TETon3G), constitutively expresses the TETon3G transactivator (Clontech, 
rtTA), a fusion protein of a Tet repressor (E. coli) mutant and three VP16 (transcription activation 
domain of herpes simplex virus). In the presence of the inducer doxycycline (dox), the TETon3G-dox 
complex binds to the TRE minimal promoter (TRE-pMCVmin) and induces the expression of the 
gene of interest (GOI).
(b)  Donor D2.2 (pMDS-GOI-TEToff) is based on the TEToff advanced inducible expression system 
(Clontech). This vector expresses the TEToff advanced transactivator (TetR) and also contains a TRE-
based module that expresses high levels of the GOI in the absence of dox.
(c)  Donor D2.3 (pMDS-GOI-TETon-PGK), is a modification of Donor D2.1, where the expression 
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Figure 1. TEMTAC system components. (a) Cre-LoxP mediated generation of plasmid fusions is shown 
in a schematic view. Acceptor A plasmid module is incubated with two Donor modules, D1 and D2 in 
the presence of Cre recombinase. Concomitant assembly (Cre) and excision (De-Cre) reactions occur 
until equilibrium is reached. Acceptor-Donor (A-D1, A-D2) and Acceptor-Donor-Donor (A-D1-D2 or 
“pTEMTAC”) fusion plasmids co-exist with educt plasmids when equilibrium is reached. Acceptor A 
contains a common origin or replication (ColE1), Donors D1 and D2 contain conditional origins of 
www.nature.com/scientificreports/
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of the rtTA is downstream of a minimal phosphoglycerate kinase (PGK) promoter (reduced basal 
expression).
(d)  Donor D2.4 (pMDS-GOI-TETon-tTS) is a modification of TETon to reduce basal expression levels. 
This is achieved by adding an internal ribosome entry site (IRES) and a tTS (Tetracycline-controlled 
transcriptional silencer, Clontech), which is a fusion of the TetR and the KRAB-AB silencing domain 
of the Kid-1 protein, after the transactivator (rtTA). As tTS competes with rtTA by binding specifi-
cally to the TRE, it suppresses the transcription in the absence of dox.
To compare their performance, we inserted the luciferase gene into D2.1 to D2.4 and monitored 
luciferase expression at increasing doxycycline concentrations in HEK293 and HeLa cells (Fig.  2a and 
Supplementary Fig. 6). In our experiments, Donor D2.4 is characterized by the lowest basal expression 
and higher dynamic range. Donor D2.3 exhibited a narrow dynamic range and medium basal levels, 
while D2.1 is intermediate in between D2.3 and D2.4. Donor D2.3 could be interesting when aiming for 
an expression level in the exponential expression range of D2.4: in this case it might be difficult to tune 
the right levels of dox for D2.4, but this should be doable if D2.3 is used. D2.2 has a high basal expression 
and can be efficiently repressed. Thus, TEMTAC offers four defined expression modalities that cover the 
requirements for the large majority of genes to be expressed.
Integrator module. The final component of TEMTAC is Acceptor A, which provides the integrator 
cassette that receives the elements from both the silencing and inducible expression modules (Fig. 2b). 
Acceptor A contains the elements required for Donor integration, construct selection, and transfection 
visualization by monitoring expression of yellow fluorescent protein (YFP). In addition to transient mul-
tigene expression by transfection, Acceptor A can also be used to generate stable cell lines, as it contains 
the elements required for stable integration of multigene constructions. To this end, two rare homing 
endonuclease sites, I-SceI and PI-PspI, are included in the Acceptor, between two eukaryotic drug selec-
tion markers for efficient linearization with these extremely rare cutters. The two resistance markers are 
flanking the multigene construction that would result from Cre-mediated Donor D1 and D2 incorpora-
tion into Acceptor A, to ensure integration of the complete multigene construction in the resulting stably 
expressing cell lines by exposure to both drugs simultaneously during selection. Moreover, Acceptor A 
also contains the flippase recognition target (Frt) site for stable integration into commercially available 
flippase (Flp)-expressing cells (i.e. Flp-In-293, Invitrogen) if desired. We tested Acceptor A by Cre-LoxP 
fusing with Donor D2.1-mCherry (containing mCherry as GOI). We observed both a high transfection 
efficiency transfection (monitored by YFP expression) and moreover also proper TET-regulated expres-
sion of the mCherry protein (Fig. 2c) and of luciferase (Fig. 2d and Supplementary Fig. 6).
Biological application. We next tested our TEMTAC system with the three oncogenic proteins 
SHP2, BRAF and HRAS. Similar as observed for luciferase assays, the three target genes could be 
expressed in a doxycycline-dependent manner to very high levels (Supplementary Figure S7 and S8). In 
all cases, we silent-mutated the GOI to be expressed exogenously, by altering the nucleotide sequence at 
the 3’prime end of the positions where the two shRNAs bind, to prevent the induction of the degrada-
tion machinery on the exogenous mRNA. We first tested the combined down-regulation of endogenous 
BRAF with exogenous complementation by a BRAF V600E cancer mutation using a Donor D2.4 variant 
(pMDS-GOI-TETon- tTS) in HEK293 cells grown in serum-containing medium. Exogenous expression 
of this oncogenic mutation tends to be higher as compared to wildtype (WT) (C. Kiel et al. submitted, 
2015). To rectify this, we took advantage of our TET-regulated system to tune the expression levels of 
replication derived from phage R6Kγ , rendering their propagation in regular cloning strains dependent 
on productive Cre fusion with Acceptor A. (b) Donor D1 (pMDC-RNAiDual) is shown in a schematic 
view. This Donor provides cassettes for multiple shRNA production. (c) shRNA-mediated downregulation 
of SHP2, HRAS and BRAF after transfection with a Donor D1 producing specific shRNAs. Transfected 
HEK293 (for HRAS and BRAF) or GH-HEK293 cells were lysed and analysed by Western blotting. (d) Four 
Donor plasmid variants D2.1 to D2.4 are shown schematically, which realize four distinct dynamic ranges of 
exogenous protein expression. Abbreviations: Cre, Cre recombinase enzyme; LoxP, imperfect inverted repeat 
recognized by Cre; GOI, gene of interest; A-D1, fusion of Acceptor A with Donor D1; A-D2, fusion of 
Acceptor A with Donor D2 (or variants); A-D1-D2, complete fusion of Acceptor A with Donors D1 and D2 
(or variants); shRNA, small hairpin RNA sequence; I-SceI, PI-PspI and PI-SceI are homing endonucleases; 
H1, U6, CMV and CAG are common mammalian active promoters; pA and SV40 are common poly-
adenylation signals; TRE-pCMVmin, tetracycline response element with minimal CMV promotor; rtTA, 
tetracycline transactivator with (random) mutagenesis derive Tet repressor part of the transactivator gene; 
Sp, Cm, Hygr and Zeo denote resistance marker genes for spectinomycin, chloramphenicol, hygromycin and 
zeocin, respectively; YFP, yellow fluorescence protein; TetR, tet repressor gene; TetR-KRAB, tetracycline-
controlled hybrid protein of TetR with the KRAB silencing domain of human Kid1; IRES, internal ribosome 
entry site; Frt, FLP recognition target; ColE1, common colicin E1 derived replication origin; R6Kγ , 
conditional origin derived from R6Kγ phage.
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WT and V600E to be close to identical (4 ng/ml of doxycycline to express WT and 2 ng/ml of doxycy-
cline to express V600E; Fig. 3a and Supplementary Fig. 9). Higher, but also similar expression levels were 
obtained by using ratios of 12(WT):20(V600E) and 6:10 ng/ml doxycycline, respectively. When compar-
ing similar protein expression levels, we found in all cases much higher MEK (gene IDs MAP2K1 and 
MAP2K2) phosphorylation levels, which characterizes this oncogenic mutation20. Secondly, we expressed 
an oncogenic mutant of HRAS (G12V) using donor D2.1 (pMDS-GOI-TETon) in HEK293 cells. Again, 
higher concentrations of doxycycline were needed for the WT construct to result in similar expression 
levels as for HRAS (Fig. 3b and Supplementary Fig. 10). As expected, the HRAS G12V mutation resulted 
Figure 2. Luciferase expression using different donor plasmids and using the assembled pTEMTAC. 
(a) Luciferase expression in HEK293 and Hela cells from the different Donor D2 versions shown in Fig. 1 
panel d. Averages and standard deviations from three biological replicates are shown. (b) Schematic view of 
Acceptor A (pAceMam3) plasmid. (c) Expression of mCherry from a complete A-D1-D2 fusion plasmid in 
HEK293 cells is shown, using different doxycycline concentrations for induction. Transfection efficiency was 
visualized by monitoring YFP fluorescence. (d) Luciferase expression in HEK293 and Hela cells from the 
different pTEMTAC plasmid. Averages and standard deviations from three biological replicates are shown. 
Abbreviations: see Figure legend 1.
www.nature.com/scientificreports/
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in higher ERK (gene IDs MAPK3 and MAPK1) phosphorylation levels. Moreover, we also tested both 
a phosphatase dead (C459G) and an activating (Noonan syndrome-causing, D61G) mutation of SHP2 
(gene ID PTPN11) using Donor D2.1 (pMDS-GOI-TETon-3G) in HEK293 cells that stably express the 
growth hormone (GH) receptor23. SHP2 WT and mutant expression levels were similar at the same 
doxycycline concentrations. At 24 h after transfection, GH-HEK293 cells were induced with 1 ng/ml dox-
ycycline in serum-free media for 24 hours. Cells were stimulated for 15 min with growth hormone, lysed 
in SDS buffer, and analysed by Western blotting (Fig. 3c and Supplementary Figure S11). Corroborating 
previous observations24, we found reduced ERK phosphorylation with the phosphatase dead (C459G 
mutation) and increased ERK signalling with the D61G mutation.
Conclusions
We created and compellingly validated TEMTAC, a novel, highly efficient system for tuneable endog-
enous mammalian target complementation. TEMTAC exploits multiplexed plasmid-based recombi-
neering, relying on automatable routines for heterologous DNA insertion and Cre-LoxP mediated 
plasmid fusion in custom-designed Acceptor and Donor plasmid modules, compatible with robotics and 
high-throughput. TEMTAC enables production of multiple different shRNAs for efficient knockdown of 
endogenous proteins combined with simultaneous, highly regulated expression of protein variants such 
Figure 3. Highly efficient wild-type down-regulation and concomitant mutant complementation for 
BRAF, HRAS and SHP2 proteins by TEMTAC. (a) Expression and phenotype analysis of BRAF V600E and 
WT in HEK293 cells is shown. Left panel: Western blot results using specific antibodies as indicated. Right 
panel: MEKp quantification after intensity analysis using ImageJ. (b) Expression and phenotype analysis of 
HRAS G12V and WT in HEK293 cells. Left panel: Western blot results using antibodies as indicated. Right 
panel: MEKp quantification after intensity analysis using ImageJ. (c) Expression and phenotype analysis of 
SHP2 C459G, D61G and WT in GH-HEK293 cells (HEK293 cells stably expressing the growth hormone 
receptor). Left panel: Western blot results using antibodies as indicated. Right panel: ERKp quantification 
after intensity analysis using ImageJ. The dashed line indicates that the blot has been cropped. The full blot 
is provided in Supplementary Figure S11.
www.nature.com/scientificreports/
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as exogenous mutants. Tuning of exogenous proteins to the desired physiological level is achieved in 
TEMTAC by provision of several different TET-inducible promotor systems covering a large dynamic 
range. Moreover, it allows for testing hypotheses on how quantitative protein level alterations may impact 
specific cellular responses. Complex multicomponent signalling systems and even complete metabolic 
pathways can be analysed by TEMTAC in this way. Furthermore, cancer phenotypes, in which a complete 
signal cascade is often mutated, can be investigated by TEMTAC, for instance by generating arrays of 
variants of cascade components that approximate the malignant mutant state.
Our system is by no means restricted to mutation analysis. TEMTAC can also be used for other 
applications, such as to express alternative spliced isoforms to reveal their cellular function. Likewise, 
protein variants such as fusion proteins can be substituted for wild-type, fine-tuned at endogenous 
levels for subsequent comprehensive functional analysis. Tags for efficient tandem affinity purification 
or fusion proteins of biotin ligase can be included to detect specific endogenous signalling complexes 
and their dynamic assembly. Moreover, genetic elements for viral encapsulation can be incorporated in 
TEMTAC, for infecting primary cells to dissect mechanisms that control cell fate. A modified version 
of the Acceptor can be used in combination with the PiggyBac system for generating stable cell lines25 
(Supplementary Figure S12). Furthermore, the presence of the fluorescent marker YFP enables cells to be 
efficiently sorted by FACS for subsequent analysis of transfected cells at the single-cell level. We anticipate 
that a wide range of applications will benefit from TEMTAC for genotype-phenotype analysis in mam-
malian systems, including genome-wide characterization of alternative splice variants, small nucleotide 
polymorphisms, mutations under various physiological-, developmental- and cell type- specific condi-
tions in health and disease states.
Methods
TEMTAC plasmid design and preparation. Plasmids Donor D1 (pMDC-RNAiDual) and Donor 
D2 (pMDS-GOI) were created based on the original plasmids of the ACEMBL system for protein 
complex expression in prokaryotic hosts15. Briefly, origins of replication, resistance markers, the loxP 
sequence, the multiplication module consisting of matching homing endonuclease site and BstXI were 
retained from the original ACEMBL Donors and the former protein expression cassettes exchanged by 
the novel production modules for producing shRNAs (D1) or the protein variant of interest (D2), respec-
tively. These novel modules were designed based on commonly used mammalian active expression cas-
settes for shRNA or genes of interest and synthesized by a commercial supplier (GenScript Corporation, 
Piscataway, NJ USA). Synthetic fragments were inserted into the DNA plasmid backbones using standard 
restriction/ligation cloning. In Donor D1 (pMDC-RNAiDual), shRNAs are bidirectionally co-expressed 
using specific polymerase III promoters H1 and U6, respectively, as previously described24. A series of 
Donor D2 plasmids was designed to enable tunable expression by adapting commercially available tet-
racycline-dependent induction (TET) modules (Clontech laboratories, Mountain View, CA USA). Thus, 
Donor D2.1 (pMDS-GOI-TETon3G) comprises a TET module derived from Tet-On 3G; Donor D2.2 
(pMDS-GOI-TEToff) a TEToff module; Donor D2.3 (pMDS-GOI-TETon-PGK) is derived from D2.1, 
however with the promotor for rtTA exchanged to a minimal promotor (PGK); Donor D2.4 (pMDS-
GOI-TETon-tTS) is derived from D2.1 however comprises a transcriptional silencer (Tet-tTS).
Plasmid Acceptor A was designed de novo from scratch. All DNA elements (YFP expression cassette, 
resistance markers, multiplication module, Frt site and homing endonuclease sites for linearization, see 
Fig. 1) were synthesized (Genscript) and combined by sequence and ligation independent cloning26.
All plasmids were verified by DNA sequencing (GATC Biotech, Cologne, Germany). Sequences are 
provided in the Supplementary Information.
DNA manipulation. shRNAs and genes of interest (GOI) were inserted into the TEMTAC system 
using standard restriction-ligation cloning methods or, alternatively, by Gibson cloning27. Cre recombi-
nase reactions were carried out according to the manufacturer’s recommendation (New England Biolabs, 
Ipswich, MA USA). Single amino acid mutations (for HRAS, SHP2, and BRAF) were introduced with 
the QuikChange site-directed mutagenesis kit (Stratagene, Santa Clara CA, USA) using Donor D2-based 
constructs as template.
Cell culture methods. HEK293, HeLa and GH-HEK293 cells were cultured in Dulbecco’s modified 
Eagle’s medium (Gibco Life Technologies, Grand Island, NY, USA) supplemented with L-glutamine and 
10% (v/v) heat-inactivated TET-free fetal calf serum (Clontech ref. 631106) (here called normal growth 
medium).
Luciferase assay. HEK293 or HeLa cells were seeded in 96-well-plates (Thermo Scientific 165306) 
and grown to 60% confluency in normal growth medium. Cells were transfected with 40 ng of the four 
different Donor D2 plasmids containing luciferase as the GOI (Donor D2.1-D2.4) or with the fully 
Cre-assembled (A-D1-D2) pTEMTAC composite plasmid (containing siRNA scramble) using lipo-
fectamine 2000 (Invitrogen, Life Technologies). 24 hours after transfection, cells were supplemented 
with indicated amounts of doxycycline (Sigma-Aldrich). 24 hour later the luciferase assay was performed 
according to the manufactures instructions (Promega Corporation, Fitchburg WI, USA).
www.nature.com/scientificreports/
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Microscopy. HEK293 cells were seeded on 6 well plates and grown to 60% confluency in normal 
growth medium. Cells were transfected with 2.5 μ g of the fully Cre-assembled A-D1-D2 compos-
ite plasmid containing mCherry as the GOI (containing siRNA scramble) using lipofectamine 2000 
(Invitrogen). 24 hours after transfection, cells were supplemented with indicated amounts of doxycy-
cline (Sigma-Aldrich, Carlsbad, CA USA). 24 h later YFP and mCherry fluorescence was imaged on an 
inverted DMI-6000 Leica wide-field fluorescent microscope equipped with a Leica DFC 350FX camera 
with a 20× objective.
Transfection, growth hormone stimulation, and cell lysis for SHP2 WT and mutants. GH-HEK293 
cells (HEK293 cells stably expressing the growth hormone receptor; gift from Armelle Yart lab) were 
seeded on 6-cm dishes in normal growth medium, grown to 60% confluency, and transfected with 
2.5 μ g of pTEMTAC (A-D1-D2) plasmid (containing SHP2 WT or mutants as GOI and the correspond-
ing RNAiDual) or, alternatively, pMDC-RNAiDual (shRNA against SHP2 or scramble shRNA) plasmid, 
using lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. 24 hours after trans-
fection, cells were supplemented with indicated amounts of doxycycline (Sigma-Aldrich) and incubated 
in minimal medium (DMEM plus 2 mM glutamine and 1% serum). 24 hours after transfection, cells were 
stimulated with 125 ng/ml growth hormone for 10 minutes, washed with PBS and resuspended in 200 μ l 
of lysis buffer [0.1% SDS, 25 mM Tris (pH 7.8), 1:1000 protease inhibitor cocktail 1 and 2 (Sigma-Aldrich)]. 
Lysed cells were analysed by western blot.
Transfection and cell lysis for HRAS and BRAF WT and mutants. HEK293 were seeded on 6-cm 
dishes in normal growth medium, grown to 60% confluency, and transfected with 2.5 μ g of pTEMTAC 
(containing BRAF/HRAS WT or V600E/G12V as GOI) or pMDC-RNAiDual (shRNA against BRAF/
HRAS or scramble shRNA) plasmid, using lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. 48 hours after transfection, cells were supplemented with indicated amounts of dox-
ycycline (Sigma-Aldrich) and incubated in normal growth medium. 24 hours after transfection, cells 
were washed with PBS and resuspended in 200 μ l of lysis buffer [0.1% SDS, 25 mM Tris (pH 7.8), 1:1000 
protease inhibitor cocktail 1 and 2 (Sigma)]. Lysed cells were analysed by western blot.
Western blot. Cell lysates were loaded on SDS gels and separated by electrophoresis; gels were then 
transferred onto nitrocellulose membrane using the iBlot system (Invitrogen), and the blots were incu-
bated 1 h at room temperature in TBS, Tween 0.1%+ 5% milk. The primary antibody was incubated 
at 4 °C overnight (1:1000 dilution), and the HRP-coupled secondary antibody (1:10 000 dilution) was 
incubated 1 h at room temperature, both in TBS Tween 0.1% + 0.5% milk. Blots were developed using 
high sensitivity ECL reagent (Thermo) and visualized using the Fujifilm LAS-3000 developer. Bands 
were analyzed using ImageJ. The following antibodies were used for Western blotting: SHP2 (Cell 
Signaling Technologies Inc, Danvers MA, USA, #3752), BRAF (SIGMA, HPA001328), total RAS (Abcam, 
Cambridge UK; ab52939), growth hormone receptor (Abcam, ab65304), phospho-ERK Thr202/Tyr204 
(Cell Signaling Technologies Inc, #9101), phospho-MEK Ser217 and Ser221 (Cell Signaling, #9121) and 
β -actin (Thermo Fischer Scientific, Waltham MA USA, MA5-15739).
Real time PCR. Cells were grown and transfected as before. RNA was isolated using miRNeasy 
Mini Kit (Qiagen) following the manufactures protocol including the optional DNase digestion step. 
PCR reactions were prepared using qPCR mix (Power SYBR® Green RNA-to-CTTM 1-Step Kit, Applied 
Biosystems), 0.15 μ M of forward and reverse primers and 60 ng of RNA following the manufactures 
instructions. For PCR the cycling parameters were (i) reverse transcription (48 °C, 30 min), (ii) activa-
tion of polymerase and initial denaturation (95 °C, 10 min), (iii) 40 cycles of denaturation (95 °C, 15 sec), 
annealing, extension and read fluorescence (60 °C, 1 min), (iv) final hold (4 °C). The following primers 
were used. For endogenous BRAF 5′ ATCCCAGAGTGCTGTGCTGT3′ (forward) and 5′ TCTCCAACA 
CTTCCACATGC3′ (reverse), for exogenous BRAF 5′ AATGTTGCGCCGTTTACAG3′ (forward) and 
5′ TCTCCAACACTTCCACATGC3′ (reverse), for endogenous HRAS 5′ TGCCATCAACAACACCAAGT
3′(forward) and 5′ ACGTCATCCGAGTCCTTCAC3′ (reverse), for exogenous HRAS 5′ GAGGGCTTCC 
TGTGTGTCTT3′ (forward) and 5′ TCTTTGACGCGCTTAATTTG3′ (reverse), for endogenous SHP2 
5′ CTTGTACTCCAACGCCACCC3′ (forward) and 5′ CTGTGCTGAAGTTTTGGCAGG3′ (reverse) 
and for total SHP2 5′ GGTGTGGAGGCAGAAAACCT3′ (forward) and 5′ TTGATGTGGGTGACAGC
TCC3′ (reverse).
Amplicon sequencing/MiSeq. RNA was extracted as described for real time PCR. cDNA synthesis 
was done using SuperScriptTM II RT (Invitrogen) with random oligonucleotides. In the first PCR all 
target genes (BRAF, HRAS, SHP2) were amplified for 5 cycles using Phusion DNA polymerase (New 
England Biolabs) with the following degenerated adaptor primers: for BRAF (region of V600E)
5′ CCCTACACGACGCTCTTCCGATCTCTTCATGAAGACCTCACAG3′ 
5′ CCCTACACGACGCTCTTCCGATCTaCTTCATGAAGACCTCACAG3′ 
5′ CCCTACACGACGCTCTTCCGATCTgaCTTCATGAAGACCTCACAG3′ 
5′ CCCTACACGACGCTCTTCCGATCTcgtCTTCATGAAGACCTCACAG3′ 
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5′ CCCTACACGACGCTCTTCCGATCTagatCTTCATGAAGACCTCACAG3′ 
(forward) and
5′ TTCAGACGTGTGCTCTTCCGATCTCTGTTCAAACTGATGGGACC3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTaCTGTTCAAACTGATGGGACC3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTgaCTGTTCAAACTGATGGGACC3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTcgtCTGTTCAAACTGATGGGACC3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTagatCTGTTCAAACTGATGGGACC3′ 
(reverse), for HRAS (region around G12V)
5′ CCCTACACGACGCTCTTCCGATCTGACGGAATATAAGCTGGTGG3′ 
5′ CCCTACACGACGCTCTTCCGATCTaGACGGAATATAAGCTGGTGG3′ 
5′ CCCTACACGACGCTCTTCCGATCTcaGACGGAATATAAGCTGGTGG3′ 
5′ CCCTACACGACGCTCTTCCGATCTgctGACGGAATATAAGCTGGTGG3′ 
5′ CCCTACACGACGCTCTTCCGATCTatcaGACGGAATATAAGCTGGTGG3′ 
(forward) and
5′ TTCAGACGTGTGCTCTTCCGATCTGTCGTATTCGTCCACAAAGTG3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTaGTCGTATTCGTCCACAAAGTG3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTcaGTCGTATTCGTCCACAAAGTG3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTatcGTCGTATTCGTCCACAAAGTG3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTatcaGTCGTATTCGTCCACAAAGTG3′ 
(reverse), for SHP2 (region around D61G)
5′ CCCTACACGACGCTCTTCCGATCTAGTAAAAGTAACCCTGGAGAC3′ 
5′ CCCTACACGACGCTCTTCCGATCTaAGTAAAAGTAACCCTGGAGAC3′ 
5′ CCCTACACGACGCTCTTCCGATCTgaAGTAAAAGTAACCCTGGAGAC3′ 
5′ CCCTACACGACGCTCTTCCGATCTtgaAGTAAAAGTAACCCTGGAGAC3′ 
5′ CCCTACACGACGCTCTTCCGATCTctgaAGTAAAAGTAACCCTGGAGAC3′ 
(forward) and
5′ TTCAGACGTGTGCTCTTCCGATCTGACCAACTCAGCCAAAGTG3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTaGACCAACTCAGCCAAAGTG3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTgaGACCAACTCAGCCAAAGTG3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTtgaGACCAACTCAGCCAAAGTG3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTctgaGACCAACTCAGCCAAAGTG3′ 
(reverse), and for SHP2 (region around C459G)
5′ CCCTACACGACGCTCTTCCGATCTGAGGTGCACCATAAGCAGGAG3′ 
5′ CCCTACACGACGCTCTTCCGATCTaGAGGTGCACCATAAGCAGGAG3′ 
5′ CCCTACACGACGCTCTTCCGATCTgaGAGGTGCACCATAAGCAGGAG3′ 
5′ CCCTACACGACGCTCTTCCGATCTtgaGAGGTGCACCATAAGCAGGAG3′ 
5’CCCTACACGACGCTCTTCCGATCTctgaGAGGTGCACCATAAGCAGGAG3′ 
(forward) and
5′ TTCAGACGTGTGCTCTTCCGATCTTCACAATGAACGTCCCTGTC3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTaTCACAATGAACGTCCCTGTC3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTgaTCACAATGAACGTCCCTGTC3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTtgaTCACAATGAACGTCCCTGTC3′ 
5′ TTCAGACGTGTGCTCTTCCGATCTctgaTCACAATGAACGTCCCTGTC3′ 
(reverse).
The resulting amplicons were used for determination of cycle numbers for the second PCR with 
the TruSeq dual barcoding primers. The primary PCR product was amplified using NEBNext 2x High 
Fidelity PCR Master Mix (New England Biolabs), with 200nM primer concentration, and 0.1x SYBR 
Green I (SIGMA Aldrich; S9430) monitoring the amplification in a Roche LightCycler 480. The cycle 
number for the final library PCR was chosen to get a sufficient amount of product without reaching the 
plateau phase of the PCR. Then 2.5 μ l of the primary PCR product was used for amplification with the 
NEBNext Master Mix and barcode primers (forward adaptor primers: 5′ -AAT GAT ACG GCG ACC 
ACC GAG ATC TAC AC [8 bp barcode] ACA CTC TTT CCC TAC ACG ACG CTC TTC-3′ ; reverse 
adaptor primers: 5′ -CAA GCA GAA GAC GGC ATA CGA GAT [8 bp barcode] GTG ACT GGA GTT 
CAG ACG TGT GCT CTT C-3′ ) but without SYBR Green, for the number of cycles determined from 
the qPCR. PCR products were purified using AMPure XP beads and concentration was determined on 
a Bioanalyzer DNA 1000 chip. Samples were sequenced using MiSeq v3 chemistry with 130 cycle single 
reads in a MiSeq sequencer (Illumina). Flanking reads were subtracted by mutant reads to calculate the 
reads corresponding to the endogenous expression level.
References
1. Ponten, F. et al. A global view of protein expression in human cells, tissues, and organs. Mol. Syst. Biol. 5, 337 (2009)
2. Geiger, T. et al. Initial quantitative proteomic map of 28 mouse tissues using the SILAC mouse. Mol. Cell. Proteomics 12, 
1709–1722 (2013)
3. Kiel, C. et al. Quantification of ErbB network proteins in three cell types using complementary approaches identifies cell-general 
and cell-type-specific signaling proteins. J. Proteome Res. 13, 300–313 (2014)
www.nature.com/scientificreports/
1 0Scientific RepoRts | 5:17432 | DOI: 10.1038/srep17432
4. Kiel, C., Verschueren, E., Yang, J. S. & Serrano, L. Integration of protein abundance and structure data reveals competition in the 
ErbB signaling network. Sci. Signal. 6, ra109 (2013).
5. Schaefer, M. H., Yang, J. S., Serrano, L. & Kiel, C. Protein conservation and variation suggest mechanisms of cell type-specific 
modulation of signaling pathways. PLoS Comput. Biol. 10, e1003659 (2014)
6. Spencer, S. L., Gaudet, S., Albeck, J. G., Burke, J. M. & Sorger, P. K. Non-genetic origins of cell-to-cell variability in TRAIL-
induced apoptosis. Nature 459, 428–432 (2009)
7. Romano, D. et al. Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling. Nat. Cell. Biol. 16, 673–684 (2014)
8. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 
494–498 (2001)
9. Brummelkamp, T. R., Bernards, R. & Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. 
Science 296, 550–553 (2002)
10. Shin, D., Lee, H., Kim, S. I., Yoon, Y. & Kim, M. Optimization of linear double-stranded RNA for the production of multiple 
siRNAs targeting hepatitis C virus. RNA 15, 898–910 (2009)
11. Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32, 347–355 
(2014)
12. Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442–451 (2013)
13. Kim, D. et al. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat. Methods 12, 237–243 
(2015)
14. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol 31, 822–826 
(2013)
15. Bieniossek, C. et al. Automated unrestricted multigene recombineering for multiprotein complex production. Nat. Methods 6, 
447–450 (2009)
16. Kriz, A. et al. A plasmid-based multigene expression system for mammalian cells. Nat. Commun. 1, 120 (2010)
17. Gossen, M. & Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. 
Acad. Sci. USA 89, 5547–5551 (1992)
18. Song, J., Giang, A., Lu, Y., Pang, S. & Chiu, R. Multiple shRNA expressing vector enhances efficiency of gene silencing. BMB Rep. 
41, 3583–62 (2008)
19. Sala, E. et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma 
and thyroid carcinoma cells. Mol. Cancer Res. 6, 751–759 (2008)
20. Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M. & Tuveson, D. A. Suppression of BRAF(V599E) in human 
melanoma abrogates transformation. Cancer Res. 63, 5198–5202 (2003)
21. Aceto, N. et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation 
of key transcription factors and a positive feedback signaling loop. Nat. Med. 18, 529–537 (2012)
22. Tsang, Y. H., Han, X., Man, W. Y., Lee, N. & Poon, R. Y. Novel functions of the phosphatase SHP2 in the DNA replication and 
damage checkpoints. PLoS One 7, e49943 (2012)
23. De Rocca Serra-Nedelec, A. et al. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via 
growth hormone-induced ERK hyperactivation, which contributes to short stature. Proc. Natl. Acad. Sci. USA 109, 4257–4262 
(2012)
24. Nagao, A. et al. Multiple shRNA expressions in a single plasmid vector improve RNAi against the XPA gene. Biochem. Biophys. 
Res. Commun. 370, 301–305 (2008)
25. Li, X. et al. PiggyBac transposase tools for genome engineering. Proc. Natl. Acad. Sci. USA. 110, E2279–2287 (2013)
26. Li, M. Z. & Elledge, S. J. Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC. Nat. Methods 
4, 251–256 (2007)
27. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343–345 (2009)
Acknowledgements
We thank all members of our laboratories for their contributions and helpful discussions. We thank the CRG 
Genomics Unit and the Biomolecular Screening & Protein Technologies Unit. We acknowledge help in the 
quantifications of the Western blots by Dina Cramer and assistance in RNA sequencing analysis by Javier 
Delgado. Armelle Yart provided the HEK293 cells stably expressing GH receptor. This work was funded by 
the European Commission (EC) Framework programme (FP) 7 projects PRIMES (contract nr. 278568), 
ComplexINC (contract nr. 279039) and SynSignal (contract nr. 613879). LS is supported by the Spanish 
Ministerio de Economía y Competitividad, Plan Nacional BIO2012-39754 and the European Fund for 
Economic and Regional Development. We are particularly grateful for the support of the Spanish Ministry 
of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013-2017′ (SEV-2012-0208).
Author Contributions
I.B., V.B.S., L.S., J.B. and C.K. designed the plasmids. C.K., V.B.S. and H.B. designed the experiments. 
V.B.S., H.B. and C.K. performed the experiments. C.K., I.B. and L.S. wrote the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: IB is inventor on patents and patent applications that comprise 
components of the system here described. The other authors declare no competing financial interests.
How to cite this article: Beltran-Sastre, V. et al. Tuneable endogenous mammalian target 
complementation via multiplexed plasmid-based recombineering. Sci. Rep. 5, 17432;  
doi: 10.1038/srep17432 (2015).
This work is licensed under a Creative Commons Attribution 4.0 International License. The 
images or other third party material in this article are included in the article’s Creative Com-
mons license, unless indicated otherwise in the credit line; if the material is not included under the 
Creative Commons license, users will need to obtain permission from the license holder to reproduce 
the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
